Singulair news from FiercePharma
NewsFDA nixes Merck, Schering allergy combo
In another blow to the Merck/Schering-Plough joint venture, the FDA rejected a proposed allergy and asthma treatment that would have Read more...
Under pharma earnings, basic problems
You've heard of see-through buildings. How about see-through pharma earnings? Though drug makers have been reporting increases to their bottom lines, investors are looking past the foreign-currency Read more...
Emerging markets drive global growth
Without emerging healthcare markets like China and India, global pharma would be in a world of hurt. The global market for meds reached $712 billion last year, according to a new report from IMS Read more...
FDA issues early-warning trifecta
It was a busy day yesterday for FDA safety reviews, with a trifecta of announcements raising questions about drugs for everything from allergies to HIV. They're all "early communications," which Read more...
Merck expects $1.8B hit on Fosamax
We all knew that losing patent protection on Fosamax would cut into Merck's sales next year. We just didn't know how much. Now we do, or at least we know Merck's best estimate: about $1.8 billion. Read more...
SPOTLIGHT: Merck profits jump by 62 percent
Merck & Co. saw its profits soar by 62 percent to $1.53 billion, on a 12 percent jump in revenue and lower admin and overhead costs; Singulair was the big seller for the quarter at $1 billion. Read more...
Merck, Schering to combine blockbusters
Why not build on success? Schering-Plough and Merck are asking the FDA to approve a pill Read more...
| Press ReleasesPRESS RELEASE: Schering-Plough/Merck Announce FDA Filing Acceptance of NDA for Loratadine/Montelukast Tablet Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet KENILWORTH and WHITEHOUSE STATION, N.J., Aug. 28 -- Read more... |
Get more Singulair coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight